NEW YORK (GenomeWeb News) – Compugen has sold nearly half of its stake in Evogene, pocketing around $3.6 million from the share sale, the Tel Aviv, Israel-based firm said today.

Compugen said that it sold one million shares in a private transaction to a single, unidentified purchaser. It said that proceeds from the sale would be used to fund general corporate purposes through mid-2010.

Following the sale, Compugen holds 1,150,000 shares of Evogene, which uses Compugen's in silico predictive discovery capabilities for agricultural applications.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.

The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.

In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.

Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.